Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.8
5.6
Journals
IJMS
Special Issues
New Trends in Neoplastic Processes and Markers
ijms-logo
Submit to IJMS Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

New Trends in Neoplastic Processes and Markers

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: closed (31 July 2023) | Viewed by 6789

Special Issue Editors

Prof. Dr. Piotr Dzięgiel

E-Mail Website
Guest Editor
1. Division of Histology and Embryology, Department of Human Morphology and Embryology, Wroclaw Medical University, Wroclaw, Poland
2. Department of Physiotherapy, Wroclaw University School of Physical Education, Wroclaw, Poland
Interests: pathomorphology; experimental oncology; neoplastic transformation processes; neoplastic process markers
Special Issues, Collections and Topics in MDPI journals
Dr. Christopher Kobierzycki

E-Mail Website
Co-Guest Editor
Division of Histology and Embryology, Department of Human Morphology and Embryology, Wroclaw Medical University, Wroclaw, Poland
Interests: pathomorphology; tumor markers; oncology; gynecology and obstetrics; gynecological oncology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Neoplastic diseases are currently one of the most common and serious medical, social and economic problems worldwide. Accurate diagnosis is the necessary prerequisite of the properly designed and rapidly carried out theranostic process. At present, we have numerous tools that we can use to diagnose and treat patients. The optimal solution seems to be combining the available methods, in order to personalize the procedure and increase the effectiveness of our activities. Statistically, mistakes may occur more often in the cases of disease entities with high prevalence rates. In view of the facts stated above, markers of the highest sensitivity and specificity profiles are urgently needed.

In our Special Issue, we intend to focus on recent studies that analyze the clinical potential of tested markers, as well as review papers that show the state of the art in the currently conducted experimental research.

Prof. Dr. Piotr Dzięgiel
Dr. Christopher Kobierzycki
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • tumor markers
  • neoplastic diseases
  • cancerogenesis
  • prognostic value
  • predictive value
  • oncologic theranostics

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

15 pages, 2988 KiB  
Article
miRNA Expression Profiles in Ovarian Endometriosis and Two Types of Ovarian Cancer—Endometriosis-Associated Ovarian Cancer and High-Grade Ovarian Cancer
by Maria Szubert, Anna Nowak-Glück, Daria Domańska-Senderowska, Bożena Szymańska, Piotr Sowa, Aleksander Rycerz and Jacek R. Wilczyński
Int. J. Mol. Sci. 2023, 24(24), 17470; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms242417470 - 14 Dec 2023
Cited by 1 | Viewed by 910
Abstract
Endometriosis-associated ovarian cancer (EOC) consisting of endometrioid cancer and clear-cell ovarian cancer could be promoted by many factors. miRNAs, which are small, non-coding molecules of RNA, are among them. The aim of this study was to detect miRNAs connected with the malignant transformation [...] Read more.
Endometriosis-associated ovarian cancer (EOC) consisting of endometrioid cancer and clear-cell ovarian cancer could be promoted by many factors. miRNAs, which are small, non-coding molecules of RNA, are among them. The aim of this study was to detect miRNAs connected with the malignant transformation of endometriosis. FFPE (formalin-fixed, paraffin-embedded) samples of 135 patients operated on for endometriosis and different types of ovarian cancer (EOC and HGSOC—high-grade serous ovarian cancer) were studied. Healthy ovarian tissue was used as a control group. From the expression panel of 754 miRNAs, 7 were chosen for further tests according to their ROC (receiver operating characteristic) curves: miR-1-3p, miR-125b-1-3p, miR-31-3p, miR-200b-3p, miR-502-5p, miR-503-5p and miR-548d-5p. Furthermore, other potentially important clinical data were analysed, which included age, BMI, Ca-125 concentration, miscarriages and deliveries and concomitant diseases such as hypertension, type 2 diabetes and smoking. Among the miRNAs, miR200b-3p had the lowest expression in neoplastic tissues. miR31-3p had the highest expression in women without any lesions in the ovaries. miR-502-5p and miR-548-5p did not differ between the studied groups. The examined miRNA panel generally distinguished significantly normal ovarian tissue and endometriosis, normal ovarian tissue and cancer, and endometriosis and cancer. The malignant transformation of endometriosis is dependent on different factors. miRNA changes are among them. The studied miRNA panel described well the differences between endometriosis and EOC but had no potential to differentiate types of ovarian cancer according to their origin. Therefore, examination of a broader miRNA panel is needed and might prove itself advantageous in clinical practice. Full article
(This article belongs to the Special Issue New Trends in Neoplastic Processes and Markers)
►▼ Show Figures

Figure 1

11 pages, 808 KiB  
Article
Serum Proteomic Profiles of Patients with High and Low Risk of Endometrial Cancer Recurrence
by Dagmara Pietkiewicz, Mikołaj Piotr Zaborowski, Kamila Jaz, Eliza Matuszewska, Agata Światły-Błaszkiewicz, Tomasz Kluz, Zenon J. Kokot, Ewa Nowak-Markwitz and Jan Matysiak
Int. J. Mol. Sci. 2023, 24(19), 14528; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms241914528 - 25 Sep 2023
Viewed by 1053
Abstract
Endometrial cancer is the most common gynecological cancer worldwide. Classifying endometrial cancer into low- or high-risk groups based on the following features is recommended: tumor grade, lymphovascular space invasion, myometrial involvement, and non-endometrioid histology. Despite the recent progress in molecular profiling of endometrial [...] Read more.
Endometrial cancer is the most common gynecological cancer worldwide. Classifying endometrial cancer into low- or high-risk groups based on the following features is recommended: tumor grade, lymphovascular space invasion, myometrial involvement, and non-endometrioid histology. Despite the recent progress in molecular profiling of endometrial cancer, a substantial group of patients are misclassified based on the current criteria. This study aimed to identify proteins that could be used as biomarkers for the stratification of endometrial cancer patients into low- or high-risk groups. The proteomic analysis of serum samples from endometrial cancer patients was performed using matrix-assisted laser desorption/ionization–time of flight mass spectrometry (MALDI-TOF MS). The data were then analyzed using chemometric algorithms to identify potential biomarkers. Nineteen precursor ions were identified as fragments of eighteen proteins which included (1) connective tissue matrix proteins, (2) cytoskeletal proteins, and (3) innate immune system molecules and stress proteins. These biomarkers could be used to stratify the high- and low-risk patients, thus enabling more precise treatment decisions. Full article
(This article belongs to the Special Issue New Trends in Neoplastic Processes and Markers)
►▼ Show Figures

Figure 1

20 pages, 6319 KiB  
Article
Cancer Stem Cell Markers—Clinical Relevance and Prognostic Value in High-Grade Serous Ovarian Cancer (HGSOC) Based on The Cancer Genome Atlas Analysis
by Natalia Iżycka, Mikołaj Piotr Zaborowski, Łukasz Ciecierski, Kamila Jaz, Sebastian Szubert, Cezary Miedziarek, Marta Rezler, Kinga Piątek-Bajan, Aneta Synakiewicz, Anna Jankowska, Marek Figlerowicz, Karolina Sterzyńska and Ewa Nowak-Markwitz
Int. J. Mol. Sci. 2023, 24(16), 12746; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms241612746 - 13 Aug 2023
Cited by 3 | Viewed by 1611
Abstract
Cancer stem cells (CSCs) may contribute to an increased risk of recurrence in ovarian cancer (OC). Further research is needed to identify associations between CSC markers and OC patients’ clinical outcomes with greater certainty. If they prove to be correct, in the future, [...] Read more.
Cancer stem cells (CSCs) may contribute to an increased risk of recurrence in ovarian cancer (OC). Further research is needed to identify associations between CSC markers and OC patients’ clinical outcomes with greater certainty. If they prove to be correct, in the future, the CSC markers can be used to help predict survival and indicate new therapeutic targets. This study aimed to determine the CSC markers at mRNA and protein levels and their association with clinical presentation, outcome, and risk of recurrence in HGSOC (High-Grade Serous Ovarian Cancer). TCGA (The Cancer Genome Atlas) database with 558 ovarian cancer tumor samples was used for the evaluation of 13 CSC markers (ALDH1A1, CD44, EPCAM, KIT, LGR5, NES, NOTCH3, POU5F1, PROM1, PTTG1, ROR1, SOX9, and THY1). Data on mRNA and protein levels assessed by microarray and mass spectrometry were retrieved from TCGA. Models to predict chemotherapy response and survival were built using multiple variables, including epidemiological data, expression levels, and machine learning methodology. ALDH1A1 and LGR5 mRNA expressions indicated a higher platinum sensitivity (p = 3.50 × 10−3; p = 0.01, respectively). POU5F1 mRNA expression marked platinum-resistant tumors (p = 9.43 × 10−3). CD44 and EPCAM mRNA expression correlated with longer overall survival (OS) (p = 0.043; p = 0.039, respectively). THY1 mRNA and protein levels were associated with worse OS (p = 0.019; p = 0.015, respectively). Disease-free survival (DFS) was positively affected by EPCAM (p = 0.004), LGR5 (p = 0.018), and CD44 (p = 0.012). In the multivariate model based on CSC marker expression, the high-risk group had 9.1 months longer median overall survival than the low-risk group (p < 0.001). ALDH1A1, CD44, EPCAM, LGR5, POU5F1, and THY1 levels in OC may be used as prognostic factors for the primary outcome and help predict the treatment response. Full article
(This article belongs to the Special Issue New Trends in Neoplastic Processes and Markers)
►▼ Show Figures

Figure 1

Review

Jump to: Research

22 pages, 676 KiB  
Review
Insights into the Relationship between Pentraxin-3 and Cancer
by Maria Bogdan, Andreea-Daniela Meca, Adina Turcu-Stiolica, Carmen Nicoleta Oancea, Roxana Kostici, Marin Valeriu Surlin and Cristina Florescu
Int. J. Mol. Sci. 2022, 23(23), 15302; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms232315302 - 4 Dec 2022
Cited by 8 | Viewed by 2661
Abstract
Although cancer can be cured if detected early and treated effectively, it is still a leading cause of death worldwide. Tumor development can be limited by an appropiate immune response, but it can be promoted by chronic extensive inflammation through metabolic dysregulation and [...] Read more.
Although cancer can be cured if detected early and treated effectively, it is still a leading cause of death worldwide. Tumor development can be limited by an appropiate immune response, but it can be promoted by chronic extensive inflammation through metabolic dysregulation and angiogenesis. In the past decade, numerous efforts have been made in order to identify novel candidates with predictive values in cancer diagnostics. In line with this, researchers have investigated the involvement of pentraxin-3 (PTX-3) in cellular proliferation and immune escape in various types of cancers, although it has not been clearly elucidated. PTX-3 is a member of the long pentraxin subfamily which plays an important role in regulating inflammation, innate immunity response, angiogenesis, and tissue remodeling. Increased synthesis of inflammatory biomarkers and activation of different cellular mechanisms can induce PTX-3 expression in various types of cells (neutrophils, monocytes, lymphocytes, myeloid dendritic cells, fibroblasts, and epithelial cells). PTX-3 has both pro- and anti-tumor functions, thus dual functions in oncogenesis. This review elucidates the potential usefulness of PTX-3 as a serum biomarker in cancer. While future investigations are needed, PTX-3 is emerging as a promising tool for cancer’s diagnosis and prognosis, and also treatment monitoring. Full article
(This article belongs to the Special Issue New Trends in Neoplastic Processes and Markers)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop